Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma (Nasdaq: LIFE), a company focused on innovative biotherapeutics, announced that Jill Broadfoot, Chief Financial Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand for registered attendees starting January 10, 2022, at 7:00 am ET, and can also be accessed on the company’s website for 90 days post-event. aTyr’s primary product candidate, ATYR1923, targets inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the appointment of Danielle Campbell as Vice President of Human Resources. Campbell will lead HR strategies, focusing on organizational development and talent management, as the company aims for growth and advanced clinical trials for its lead candidate, ATYR1923. CEO Sanjay Shukla emphasized her relevant experience as beneficial for the company's transition. Campbell has 15 years in biotech HR roles and received a stock option grant of 70,000 shares at $7.77 each, vesting over four years.
aTyr Pharma (Nasdaq: LIFE) announced a novel approach to generating new antibody candidates at the Antibody Engineering & Therapeutics Conference from December 12-16, 2021. Their presentation will highlight the practical utility of repertoire data for antibody affinity maturation, enhancing existing methods with minimal effort. This technique complements their tRNA synthetase platform, which focuses on creating biologics to modulate novel biological pathways. The workshop will be presented by Senior Scientist Luke Burman on December 12 at 11:15 AM PST.
aTyr Pharma (Nasdaq: LIFE) announced a manufacturing agreement with FUJIFILM Diosynth Biotechnologies for ATYR1923, its lead candidate for pulmonary sarcoidosis. The partnership aims to support the development and scale-up of ATYR1923, including bulk drug substance production for upcoming clinical trials. This collaboration is critical as aTyr prepares for late-stage clinical development and a potential Biologics License Application. The agreement underscores aTyr's commitment to delivering innovative treatments for inflammatory lung diseases.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced that President and CEO Sanjay S. Shukla will present at two virtual investor conferences in November 2021. The first event is the Stifel 2021 Virtual Healthcare Conference on November 17 at 4:40 PM EST. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 AM EST. Management will also participate in one-on-one meetings with registered investors. Replay options will be available on the company’s website following the events.
aTyr Pharma reported positive results from the Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis, providing proof-of-concept for its tRNA synthetase biology platform. The registrational trial is expected to begin in 2022. The company raised $80 million in a common stock offering in September 2021. Q3 2021 results showed cash reserves of $116.4 million, with R&D expenses at $5.1 million. No serious adverse events were reported in the study, and improvements in lung function and symptom measures were observed.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced preclinical findings for ATYR2810 at the SITC Annual Meeting, showcasing its potential to affect tumor-associated macrophages (TAMs) in cancer treatment. The study indicates that ATYR2810, an anti-NRP2 monoclonal antibody, may reduce the suppressive ability of TAMs against T cells and lower ZEB1 gene expression, linked to tumor progression. These insights underscore the drug's potential as a therapy for aggressive cancers, with a Phase 1 study planned for next year.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced that it will report its third quarter 2021 financial results and provide a corporate update after market close on November 10, 2021. A conference call and webcast will be held the same day at 5:00 pm EST to discuss the results and operational updates. aTyr focuses on developing innovative medicines based on tRNA synthetases and is primarily advancing ATYR1923, which targets Neuropilin-2 to manage inflammatory lung diseases. For further details, visit aTyr's website.
On October 11, 2021, aTyr Pharma (Nasdaq: LIFE) announced that its CEO, Sanjay S. Shukla, will participate in a fireside chat during the Piper Sandler Virtual Investor Day on October 15, 2021, at 9:00 AM ET. The event focuses on developing therapeutics for lung indications and will be moderated by Ted Tenthoff, a Senior Research Analyst at Piper Sandler. A replay of the discussion will be available on aTyr's investor website for 90 days following the event. aTyr Pharma specializes in innovative medicines based on tRNA synthetases for inflammatory lung diseases.
aTyr Pharma (Nasdaq: LIFE) announced the appointment of Robert W. Ashworth, Ph.D., as Vice President of Regulatory Affairs. Dr. Ashworth brings over 35 years of experience, having contributed to the FDA approval of more than 12 new drugs. He will oversee regulatory strategies for aTyr's pipeline, including the advancement of ATYR1923 for pulmonary sarcoidosis and ATYR2810 for cancer trials expected next year. A stock option grant of 70,000 shares with an exercise price of $8.73 was also awarded to him, effective October 4, 2021.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
